International comparative analysis of innovation recognition and price management of new drugs from the perspective of national healthcare security
- VernacularTitle:医保视角下新药创新性认定与价格管理政策的国际对比分析
- Author:
Kaifeng MAO
1
;
Jie YU
1
;
Linning WANG
1
;
Yun LU
1
;
Feng CHANG
1
Author Information
1. School of International Pharmaceutical Business，China Pharmaceutical University，Nanjing 211198，China
- Publication Type:Journal Article
- Keywords:
innovative drug;
innovation recognition;
differentiated pricing;
level-to-level administration;
drug price management
- From:
China Pharmacy
2024;35(15):1801-1806
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide reference for the improvement of the price system of innovative drugs in China. METHODS Based on the current situation of innovative drug healthcare management in China， innovation recognition and price management of innovative drugs in typical countries or regions were compared and analyzed， and the suggestions were put forward to improve the price system of innovative drugs in China. RESULTS & CONCLUSIONS Taiwan of China， Japan， Australia， Germany and the United Kingdom have different practices in recognition and grading of drug innovation， differentiated pricing and subsequent price management. However， the mainstream practice is to identify and grade drugs mostly based on clinical value， differentiate pricing based on the grading， and carry out risk-sharing agreement or active price adjustment to manage the price. Based on the comparative analysis， it is suggested that China should further clarify the connotation and classification of innovation in the management of innovative drugs， apply a variety of pricing methods to promote differentiated management of innovative drugs， explore the introduction of risk-sharing agreements， and further build an active drug price adjustment mechanism to improve the price system of innovative drugs in China.
